Loading…
Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes
We previously reported the development of PE38KDEL-loaded anti-HER2 poly(lactic-co-glycolic acid) (PLGA) nanoparticles that bind and internalize in HER2-overexpressing breast cancer cells, enabling potent anti-tumor activity. To overcome the problems associated with the short half-lives of this drug...
Saved in:
Published in: | International journal of pharmaceutics 2009-06, Vol.374 (1), p.145-152 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443 |
---|---|
cites | cdi_FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443 |
container_end_page | 152 |
container_issue | 1 |
container_start_page | 145 |
container_title | International journal of pharmaceutics |
container_volume | 374 |
creator | Gao, Jie Zhong, Wei He, Jinqiu Li, Huimei Zhang, He Zhou, Guichen Li, Bohua Lu, Ying Zou, Hao Kou, Geng Zhang, Dapeng Wang, Hao Guo, Yajun Zhong, Yanqiang |
description | We previously reported the development of PE38KDEL-loaded anti-HER2 poly(lactic-co-glycolic acid) (PLGA) nanoparticles that bind and internalize in HER2-overexpressing breast cancer cells, enabling potent anti-tumor activity. To overcome the problems associated with the short half-lives of this drug delivery system, we have constructed PE38KDEL-loaded anti-HER2 PEGylated liposomes (PE-HER-liposomes). PE-HER-liposomes were constructed with Fab′ of recombinant humanized anti-HER2 monoclonal antibody (anti-HER2 Fab′) covalently linked to PEGylated liposomes containing PE38KDEL (PE-liposomes). We attached anti-HER2 Fab′ to the terminus of PEG (polyethylene glycol) on PEGylated liposomes. Incorporation of pyridylthiopropionoylamino-PEG-distearoylphosphatidylethanolamine (PDP-PEG-DSPE) into PEGylated liposomes followed by mild thiolysis of the PDP groups resulted in the formation of reactive thiol groups at the periphery of the liposomes. Efficient attachment of maleimide-derivatized anti-HER2 Fab′ took place under mild conditions. The characterization of PE-HER-liposomes, such as particle size, was evaluated by dynamic light-scattering detector. The Micro BCA method was used to determine the encapsulation efficiency of PE38KDEL and the quantity of conjugated Fab′. Flow cytometry and confocal microscopy showed that PE-HER-liposomes possessed receptor-specific binding and internalization for HER2-overexpressing SK-BR3 cells. Remarkably, PE-HER-liposomes were more cytotoxic than non-targeted PE-liposomes in HER2-overexpressing breast cancer cells. In conclusion, PE-HER-liposomes could serve as a promising therapeutic candidate for the treatment of HER2-overexpressing breast cancers. |
doi_str_mv | 10.1016/j.ijpharm.2009.03.018 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20644085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517309001434</els_id><sourcerecordid>20644085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443</originalsourceid><addsrcrecordid>eNqFkE1P20AQhleoCFLgJ1DlUm42s9_2qaogJYhIIATn1WY9phv5I921I-Xfs1Gs9tjTSDPPzLx6CLmmkFOg6naT-832tw1tzgDKHHgOtDghM1ponnGh1RcyA66LTFLNz8nXGDcAoBjlZ-SclkIoremMLN_Gtg_ZYMMHDljNXxa8eLpfrOYVNn6HYT_feZu6D_vGHua2G3y2XLyyuW_bsesbv-1j32K8JKe1bSJeTfWCvP9avN0ts9Xzw-Pdz1XmBBNDSiZVCVyJQhaWr63Qdal5xVjlaAkgFZcKNEuA1KLmkmmEEtayLoW2KTW_IDfHu9vQ_xkxDqb10WHT2A77MRoGSggoZALlEXShjzFgbbbBtzbsDQVzUGg2ZlJoDgoNcJMUpr1v04Nx3WL1b2tyloDvE2Cjs00dbOd8_MsxKoVgJU_cjyOHScfOYzDReewcVj6gG0zV-_9E-QTmyI52</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20644085</pqid></control><display><type>article</type><title>Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes</title><source>Elsevier</source><creator>Gao, Jie ; Zhong, Wei ; He, Jinqiu ; Li, Huimei ; Zhang, He ; Zhou, Guichen ; Li, Bohua ; Lu, Ying ; Zou, Hao ; Kou, Geng ; Zhang, Dapeng ; Wang, Hao ; Guo, Yajun ; Zhong, Yanqiang</creator><creatorcontrib>Gao, Jie ; Zhong, Wei ; He, Jinqiu ; Li, Huimei ; Zhang, He ; Zhou, Guichen ; Li, Bohua ; Lu, Ying ; Zou, Hao ; Kou, Geng ; Zhang, Dapeng ; Wang, Hao ; Guo, Yajun ; Zhong, Yanqiang</creatorcontrib><description>We previously reported the development of PE38KDEL-loaded anti-HER2 poly(lactic-co-glycolic acid) (PLGA) nanoparticles that bind and internalize in HER2-overexpressing breast cancer cells, enabling potent anti-tumor activity. To overcome the problems associated with the short half-lives of this drug delivery system, we have constructed PE38KDEL-loaded anti-HER2 PEGylated liposomes (PE-HER-liposomes). PE-HER-liposomes were constructed with Fab′ of recombinant humanized anti-HER2 monoclonal antibody (anti-HER2 Fab′) covalently linked to PEGylated liposomes containing PE38KDEL (PE-liposomes). We attached anti-HER2 Fab′ to the terminus of PEG (polyethylene glycol) on PEGylated liposomes. Incorporation of pyridylthiopropionoylamino-PEG-distearoylphosphatidylethanolamine (PDP-PEG-DSPE) into PEGylated liposomes followed by mild thiolysis of the PDP groups resulted in the formation of reactive thiol groups at the periphery of the liposomes. Efficient attachment of maleimide-derivatized anti-HER2 Fab′ took place under mild conditions. The characterization of PE-HER-liposomes, such as particle size, was evaluated by dynamic light-scattering detector. The Micro BCA method was used to determine the encapsulation efficiency of PE38KDEL and the quantity of conjugated Fab′. Flow cytometry and confocal microscopy showed that PE-HER-liposomes possessed receptor-specific binding and internalization for HER2-overexpressing SK-BR3 cells. Remarkably, PE-HER-liposomes were more cytotoxic than non-targeted PE-liposomes in HER2-overexpressing breast cancer cells. In conclusion, PE-HER-liposomes could serve as a promising therapeutic candidate for the treatment of HER2-overexpressing breast cancers.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2009.03.018</identifier><identifier>PMID: 19446771</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>ADP Ribose Transferases - immunology ; ADP Ribose Transferases - pharmacokinetics ; ADP Ribose Transferases - pharmacology ; Bacterial Toxins - immunology ; Bacterial Toxins - pharmacokinetics ; Bacterial Toxins - pharmacology ; Biological and medical sciences ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - immunology ; Cell Line, Tumor ; Cytotoxicity ; Drug Delivery Systems ; Exotoxins - immunology ; Exotoxins - pharmacokinetics ; Exotoxins - pharmacology ; Female ; Flow Cytometry ; General pharmacology ; Half-Life ; Humans ; Immunoglobulin Fab Fragments - immunology ; Liposomes ; Medical sciences ; Particle Size ; PE38KDEL ; PEGylated immunoliposomes ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Polyethylene Glycols - chemistry ; Pseudomonas aeruginosa Exotoxin A ; Receptor, ErbB-2 - immunology ; RhuMAbHER2 ; Sulfhydryl Compounds - chemistry ; Virulence Factors - immunology ; Virulence Factors - pharmacokinetics ; Virulence Factors - pharmacology</subject><ispartof>International journal of pharmaceutics, 2009-06, Vol.374 (1), p.145-152</ispartof><rights>2009 Elsevier B.V.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443</citedby><cites>FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21544293$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19446771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gao, Jie</creatorcontrib><creatorcontrib>Zhong, Wei</creatorcontrib><creatorcontrib>He, Jinqiu</creatorcontrib><creatorcontrib>Li, Huimei</creatorcontrib><creatorcontrib>Zhang, He</creatorcontrib><creatorcontrib>Zhou, Guichen</creatorcontrib><creatorcontrib>Li, Bohua</creatorcontrib><creatorcontrib>Lu, Ying</creatorcontrib><creatorcontrib>Zou, Hao</creatorcontrib><creatorcontrib>Kou, Geng</creatorcontrib><creatorcontrib>Zhang, Dapeng</creatorcontrib><creatorcontrib>Wang, Hao</creatorcontrib><creatorcontrib>Guo, Yajun</creatorcontrib><creatorcontrib>Zhong, Yanqiang</creatorcontrib><title>Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>We previously reported the development of PE38KDEL-loaded anti-HER2 poly(lactic-co-glycolic acid) (PLGA) nanoparticles that bind and internalize in HER2-overexpressing breast cancer cells, enabling potent anti-tumor activity. To overcome the problems associated with the short half-lives of this drug delivery system, we have constructed PE38KDEL-loaded anti-HER2 PEGylated liposomes (PE-HER-liposomes). PE-HER-liposomes were constructed with Fab′ of recombinant humanized anti-HER2 monoclonal antibody (anti-HER2 Fab′) covalently linked to PEGylated liposomes containing PE38KDEL (PE-liposomes). We attached anti-HER2 Fab′ to the terminus of PEG (polyethylene glycol) on PEGylated liposomes. Incorporation of pyridylthiopropionoylamino-PEG-distearoylphosphatidylethanolamine (PDP-PEG-DSPE) into PEGylated liposomes followed by mild thiolysis of the PDP groups resulted in the formation of reactive thiol groups at the periphery of the liposomes. Efficient attachment of maleimide-derivatized anti-HER2 Fab′ took place under mild conditions. The characterization of PE-HER-liposomes, such as particle size, was evaluated by dynamic light-scattering detector. The Micro BCA method was used to determine the encapsulation efficiency of PE38KDEL and the quantity of conjugated Fab′. Flow cytometry and confocal microscopy showed that PE-HER-liposomes possessed receptor-specific binding and internalization for HER2-overexpressing SK-BR3 cells. Remarkably, PE-HER-liposomes were more cytotoxic than non-targeted PE-liposomes in HER2-overexpressing breast cancer cells. In conclusion, PE-HER-liposomes could serve as a promising therapeutic candidate for the treatment of HER2-overexpressing breast cancers.</description><subject>ADP Ribose Transferases - immunology</subject><subject>ADP Ribose Transferases - pharmacokinetics</subject><subject>ADP Ribose Transferases - pharmacology</subject><subject>Bacterial Toxins - immunology</subject><subject>Bacterial Toxins - pharmacokinetics</subject><subject>Bacterial Toxins - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - immunology</subject><subject>Cell Line, Tumor</subject><subject>Cytotoxicity</subject><subject>Drug Delivery Systems</subject><subject>Exotoxins - immunology</subject><subject>Exotoxins - pharmacokinetics</subject><subject>Exotoxins - pharmacology</subject><subject>Female</subject><subject>Flow Cytometry</subject><subject>General pharmacology</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Immunoglobulin Fab Fragments - immunology</subject><subject>Liposomes</subject><subject>Medical sciences</subject><subject>Particle Size</subject><subject>PE38KDEL</subject><subject>PEGylated immunoliposomes</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Pseudomonas aeruginosa Exotoxin A</subject><subject>Receptor, ErbB-2 - immunology</subject><subject>RhuMAbHER2</subject><subject>Sulfhydryl Compounds - chemistry</subject><subject>Virulence Factors - immunology</subject><subject>Virulence Factors - pharmacokinetics</subject><subject>Virulence Factors - pharmacology</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqFkE1P20AQhleoCFLgJ1DlUm42s9_2qaogJYhIIATn1WY9phv5I921I-Xfs1Gs9tjTSDPPzLx6CLmmkFOg6naT-832tw1tzgDKHHgOtDghM1ponnGh1RcyA66LTFLNz8nXGDcAoBjlZ-SclkIoremMLN_Gtg_ZYMMHDljNXxa8eLpfrOYVNn6HYT_feZu6D_vGHua2G3y2XLyyuW_bsesbv-1j32K8JKe1bSJeTfWCvP9avN0ts9Xzw-Pdz1XmBBNDSiZVCVyJQhaWr63Qdal5xVjlaAkgFZcKNEuA1KLmkmmEEtayLoW2KTW_IDfHu9vQ_xkxDqb10WHT2A77MRoGSggoZALlEXShjzFgbbbBtzbsDQVzUGg2ZlJoDgoNcJMUpr1v04Nx3WL1b2tyloDvE2Cjs00dbOd8_MsxKoVgJU_cjyOHScfOYzDReewcVj6gG0zV-_9E-QTmyI52</recordid><startdate>20090605</startdate><enddate>20090605</enddate><creator>Gao, Jie</creator><creator>Zhong, Wei</creator><creator>He, Jinqiu</creator><creator>Li, Huimei</creator><creator>Zhang, He</creator><creator>Zhou, Guichen</creator><creator>Li, Bohua</creator><creator>Lu, Ying</creator><creator>Zou, Hao</creator><creator>Kou, Geng</creator><creator>Zhang, Dapeng</creator><creator>Wang, Hao</creator><creator>Guo, Yajun</creator><creator>Zhong, Yanqiang</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope></search><sort><creationdate>20090605</creationdate><title>Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes</title><author>Gao, Jie ; Zhong, Wei ; He, Jinqiu ; Li, Huimei ; Zhang, He ; Zhou, Guichen ; Li, Bohua ; Lu, Ying ; Zou, Hao ; Kou, Geng ; Zhang, Dapeng ; Wang, Hao ; Guo, Yajun ; Zhong, Yanqiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>ADP Ribose Transferases - immunology</topic><topic>ADP Ribose Transferases - pharmacokinetics</topic><topic>ADP Ribose Transferases - pharmacology</topic><topic>Bacterial Toxins - immunology</topic><topic>Bacterial Toxins - pharmacokinetics</topic><topic>Bacterial Toxins - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - immunology</topic><topic>Cell Line, Tumor</topic><topic>Cytotoxicity</topic><topic>Drug Delivery Systems</topic><topic>Exotoxins - immunology</topic><topic>Exotoxins - pharmacokinetics</topic><topic>Exotoxins - pharmacology</topic><topic>Female</topic><topic>Flow Cytometry</topic><topic>General pharmacology</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Immunoglobulin Fab Fragments - immunology</topic><topic>Liposomes</topic><topic>Medical sciences</topic><topic>Particle Size</topic><topic>PE38KDEL</topic><topic>PEGylated immunoliposomes</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Pseudomonas aeruginosa Exotoxin A</topic><topic>Receptor, ErbB-2 - immunology</topic><topic>RhuMAbHER2</topic><topic>Sulfhydryl Compounds - chemistry</topic><topic>Virulence Factors - immunology</topic><topic>Virulence Factors - pharmacokinetics</topic><topic>Virulence Factors - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gao, Jie</creatorcontrib><creatorcontrib>Zhong, Wei</creatorcontrib><creatorcontrib>He, Jinqiu</creatorcontrib><creatorcontrib>Li, Huimei</creatorcontrib><creatorcontrib>Zhang, He</creatorcontrib><creatorcontrib>Zhou, Guichen</creatorcontrib><creatorcontrib>Li, Bohua</creatorcontrib><creatorcontrib>Lu, Ying</creatorcontrib><creatorcontrib>Zou, Hao</creatorcontrib><creatorcontrib>Kou, Geng</creatorcontrib><creatorcontrib>Zhang, Dapeng</creatorcontrib><creatorcontrib>Wang, Hao</creatorcontrib><creatorcontrib>Guo, Yajun</creatorcontrib><creatorcontrib>Zhong, Yanqiang</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gao, Jie</au><au>Zhong, Wei</au><au>He, Jinqiu</au><au>Li, Huimei</au><au>Zhang, He</au><au>Zhou, Guichen</au><au>Li, Bohua</au><au>Lu, Ying</au><au>Zou, Hao</au><au>Kou, Geng</au><au>Zhang, Dapeng</au><au>Wang, Hao</au><au>Guo, Yajun</au><au>Zhong, Yanqiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2009-06-05</date><risdate>2009</risdate><volume>374</volume><issue>1</issue><spage>145</spage><epage>152</epage><pages>145-152</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>We previously reported the development of PE38KDEL-loaded anti-HER2 poly(lactic-co-glycolic acid) (PLGA) nanoparticles that bind and internalize in HER2-overexpressing breast cancer cells, enabling potent anti-tumor activity. To overcome the problems associated with the short half-lives of this drug delivery system, we have constructed PE38KDEL-loaded anti-HER2 PEGylated liposomes (PE-HER-liposomes). PE-HER-liposomes were constructed with Fab′ of recombinant humanized anti-HER2 monoclonal antibody (anti-HER2 Fab′) covalently linked to PEGylated liposomes containing PE38KDEL (PE-liposomes). We attached anti-HER2 Fab′ to the terminus of PEG (polyethylene glycol) on PEGylated liposomes. Incorporation of pyridylthiopropionoylamino-PEG-distearoylphosphatidylethanolamine (PDP-PEG-DSPE) into PEGylated liposomes followed by mild thiolysis of the PDP groups resulted in the formation of reactive thiol groups at the periphery of the liposomes. Efficient attachment of maleimide-derivatized anti-HER2 Fab′ took place under mild conditions. The characterization of PE-HER-liposomes, such as particle size, was evaluated by dynamic light-scattering detector. The Micro BCA method was used to determine the encapsulation efficiency of PE38KDEL and the quantity of conjugated Fab′. Flow cytometry and confocal microscopy showed that PE-HER-liposomes possessed receptor-specific binding and internalization for HER2-overexpressing SK-BR3 cells. Remarkably, PE-HER-liposomes were more cytotoxic than non-targeted PE-liposomes in HER2-overexpressing breast cancer cells. In conclusion, PE-HER-liposomes could serve as a promising therapeutic candidate for the treatment of HER2-overexpressing breast cancers.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>19446771</pmid><doi>10.1016/j.ijpharm.2009.03.018</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-5173 |
ispartof | International journal of pharmaceutics, 2009-06, Vol.374 (1), p.145-152 |
issn | 0378-5173 1873-3476 |
language | eng |
recordid | cdi_proquest_miscellaneous_20644085 |
source | Elsevier |
subjects | ADP Ribose Transferases - immunology ADP Ribose Transferases - pharmacokinetics ADP Ribose Transferases - pharmacology Bacterial Toxins - immunology Bacterial Toxins - pharmacokinetics Bacterial Toxins - pharmacology Biological and medical sciences Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - immunology Cell Line, Tumor Cytotoxicity Drug Delivery Systems Exotoxins - immunology Exotoxins - pharmacokinetics Exotoxins - pharmacology Female Flow Cytometry General pharmacology Half-Life Humans Immunoglobulin Fab Fragments - immunology Liposomes Medical sciences Particle Size PE38KDEL PEGylated immunoliposomes Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Polyethylene Glycols - chemistry Pseudomonas aeruginosa Exotoxin A Receptor, ErbB-2 - immunology RhuMAbHER2 Sulfhydryl Compounds - chemistry Virulence Factors - immunology Virulence Factors - pharmacokinetics Virulence Factors - pharmacology |
title | Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T23%3A14%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor-targeted%20PE38KDEL%20delivery%20via%20PEGylated%20anti-HER2%20immunoliposomes&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Gao,%20Jie&rft.date=2009-06-05&rft.volume=374&rft.issue=1&rft.spage=145&rft.epage=152&rft.pages=145-152&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/j.ijpharm.2009.03.018&rft_dat=%3Cproquest_cross%3E20644085%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c424t-345690364858a3ba47f973d22dc190056356072364574f3527e090b5f947a9443%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20644085&rft_id=info:pmid/19446771&rfr_iscdi=true |